	S. See C.						cu.			
Forn (Rev. 2-88)	1449	U.S.	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			атту. доскет no. 6460-40		Sheet 1 of 1  APPLICATION NO. 10/075,499		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					APPLICANT Debinski et al.					
(Use several sheets if necessary)					Filing date GROUP February 12, 2002					
			U.S	. PATENT DOCUMENTS			·			
EXAMINER'S INITIAL		DOCUMENT NUMBER	DATE	NAME		CLASS	SUBCLASS		LING DATE PPROPRIATE	
		6,124,133	9/26/00	Taylor et al.						
							RE	CE	IVED	
							SE	P 0 -	3 2002	
							TECH CE	NTER	1600/2900	
			FORE	GN PATENT DOCUMENT	s					
		DOCUMENT NUMBER	DATE COUNTRY			CLASS	SUBCLASS	TRANSLATION		
		NUMBER						YES	NO	
		· <del></del>								
		OTUED	DOCUMENTS (L	adviding Andrew Title Date	Pantin and A	Parama E(n.)				
The		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  Bhattacharya et al., "Regulation of the Urokinase-type Plasminogen Activator Receptor Gene in Different Grades of Human Glioma Cell Lines," Clinical Cancer Research, 7: 267-276, 2001								
TMC TMC		Won et al., "Stimulation of astrocyte-enriched culture with arachidonic acid increases proenkephalin mRNA: involvement of proto-oncoprotein and mitogen activated protein kinases," Molecular Brain Research, 76: 396-406, 2000								
The		Kustikova et al., "Fra-1 Induces Morphological Transformation and Increases In Vitro Invasiveness and Motility of Epitheliod Adenocarcinoma Cells," Molecular and Cellular Biology, 18: 7095-7105, 1998								
Ame		Chiappetta et al., "FRA-1 Expression in Hyperplastic and Neoplastic Thyroid Diseases <sup>1</sup> ," Clinical Cancer Research, 6: 4300-4307, 2000								
The the		Debinski et al., "VEGF-D is an X-linked/AP-1 Regulated Putative Onco-angiogen in Human Glioblastoma Multiforme," Molecular Medicine 7: 598-608, 2001								
EXAMINER (	7	ana	X20.	DATE CONSIDER	ED /	2/12/	~ V	<del></del>		

\* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.